BCYC
- Bicycle Therapeutics plc
()
Overview
Company Summary
Bicycle Therapeutics plc (BCYC) is a biotechnology company that specializes in developing and commercializing a unique class of therapeutics called Bicycle peptides. The company's focus lies in creating innovative therapies for various diseases, including cancer and other serious conditions.
Bicycle peptides are small molecules that combine the properties of both conventional small molecules and large antibodies. These peptides are derived from a bicycle-shaped framework, giving them their name, and are engineered to selectively target specific disease-related proteins. This targeted approach allows for the design of highly potent and specific treatments with reduced off-target effects.
Through its proprietary technology platform, BCYC designs and develops Bicycle peptides to selectively bind to specific disease targets, such as cell surface receptors or intracellular proteins. By doing so, they can modulate the activity of these targets, either by enhancing their function or blocking their action, ultimately resulting in therapeutic benefits.
The company's pipeline includes multiple programs, each focused on addressing a specific disease area. These include collaborations with leading pharmaceutical companies to develop Bicycle peptides against their targets of interest. BCYC also works independently to develop its own pipeline of novel therapeutics.
Bicycle Therapeutics aims to revolutionize the field of therapeutics by providing a powerful and versatile platform for developing targeted treatments. By leveraging the unique properties of Bicycle peptides, the company seeks to advance new drug candidates that can be more effective, have fewer side effects, and potentially fill unmet medical needs in various diseases.